Recent advancements in cancer vaccine development have demonstrated their potential for precise tumor targeting through ...

Janux provided a program update on its Phase 1 study of JANX008, an EGFR-targeted TRACTr, following Phase 1a completion and ...

At the recent American Society of Hematology annual meeting, phase I data highlighted a next-generation, CD19-targeted, interleukin-18-secreting "armored" CAR T-cell therapy that is designed to ...

It was the best of times, it was the worst of times for research in 2025. | It was the best of times and it was the worst of times for research in 2025. Medical breakthroughs and stunning discoveries ...

Secura Bio, Inc. ( an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology medicines, today announced that Chip Romp, Chief Executive ...

Vyriad announced $25M final tranche of its Series B to support the first-in-human testing of VV169, Vyriad’s in vivo CAR-T ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") , a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported ...

Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel ...

LBL-047 (DNTH212) is a bifunctional fusion protein targeting plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, ...

Immutep ( ($IMMP) ) has issued an announcement. On 22 December 2025, Immutep reported positive initial results from a placebo-controlled, ...

Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

EUDA” or “the Company”, a Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced a significant acceleration of its longevity and ...